HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma

Summary

This is a mono-center open-label proof-of-concept pharmacologic study to explore the efficacy and safety of vorinostat in advanced BRAF mutated melanoma, which became resistant for BRAF-inhibitors or the combination of BRAF- and MEK-inhibitors.

Timeline

Start

2016-06

Primary completion

2023-11

Completion

2023-11

Publications

• Huijberts S, Wang L, de Oliveira RL, Rosing H, Nuijen B, Beijnen J, Bernards R, Schellens J, Wilgenhof S. Vorinostat in patients with resistant BRAFV600E mutated advanced melanoma: a proof of concept study. Future Oncol. 2020 Apr;16(11):619-629. doi: 10.2217/fon-2020-0023. Epub 2020 Mar 3.

Drugs

Indications